Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

被引：1980

作者：

Inzucchi, Silvio E. ^{[1
]}

Bergenstal, Richard M. ^{[2
]}

Buse, John B. ^{[3
]}

Diamant, Michaela ^{[4
]}

Ferrannini, Ele ^{[5
]}

Nauck, Michael ^{[6
]}

Peters, Anne L. ^{[7
]}

Tsapas, Apostolos ^{[8
]}

Wender, Richard ^{[9
,10
]}

Matthews, David R. ^{[11
,12
,13
]}

机构：

[1] Yale Univ, Yale New Haven Hosp, Sch Med, Sect Endocrinol, New Haven, CT 06520 USA

[2] Int Diabet Ctr Pk Nicollet, Minneapolis, MN USA

[3] Univ N Carolina, Sch Med, Div Endocrinol, Chapel Hill, NC USA

[4] Vrije Univ Amsterdam, Med Ctr, Dept Internal Med, Diabet Ctr, Amsterdam, Netherlands

[5] Univ Pisa, Sch Med, Dept Med, I-56100 Pisa, Italy

[6] Diabet Zentrum Bad Lauterberg, Bad Lauterberg im Harz, Germany

[7] Univ So Calif, Keck Sch Med, Div Endocrinol, Los Angeles, CA 90033 USA

[8] Aristotle Univ Thessaloniki, Dept Med 2, GR-54006 Thessaloniki, Greece

[9] Amer Canc Soc, Atlanta, GA 30329 USA

[10] Thomas Jefferson Univ, Jefferson Med Coll, Dept Family & Community Med, Philadelphia, PA 19107 USA

[11] Churchill Hosp, Oxford Ctr Diabet Endocrinol & Metab, Oxford OX3 7LJ, England

[12] Oxford Biomed Res Ctr, Natl Inst Hlth Res NIHR, Oxford, England

[13] Univ Oxford, Harris Manchester Coll, Oxford, England

来源：

DIABETES CARE | 2015年 / 38卷 / 01期

关键词：

INADEQUATE GLYCEMIC CONTROL; INTENSIVE INSULIN THERAPY; BASAL INSULIN; DOUBLE-BLIND; COMBINATION THERAPY; PIOGLITAZONE USE; SGLT2; INHIBITOR; GLUCOSE CONTROL; CLINICAL-TRIAL; ADD-ON;

D O I：

10.2337/dc14-2441

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：140 / 149

页数：10

共 62 条

[1] [Anonymous], J DIABETES COMPLICAT
[2] [Anonymous], FDA BRIEF DOC INV CA
[3] [Anonymous], 2009, TYP 2 DIAB MAN TYP 2
[4] [Anonymous], EUR J ENDOCRINOL
[5] Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications
Bakris, George L.
Fonseca, Vivian A.
Sharma, Kumar
Wright, Ernest M.
[J]. KIDNEY INTERNATIONAL, 2009, 75 (12) : 1272 - 1277
[6] Balaji V, 2014, Indian J Endocrinol Metab, V18, P425, DOI 10.4103/2230-8210.131223
[7] Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature
Balena, R.
Hensley, I. E.
Miller, S.
Barnett, A. H.
[J]. DIABETES OBESITY & METABOLISM, 2013, 15 (06) : 485 - 502
[8] Bonaca MP, 2014, CIRCULATION, V130
[9] Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study
Bosi, E.
Ellis, G. C.
Wilson, C. A.
Fleck, P. R.
[J]. DIABETES OBESITY & METABOLISM, 2011, 13 (12) : 1088 - 1096
[10] Use of Twice-Daily Exenatide in Basal Insulin-Treated Patients With Type 2 Diabetes A Randomized, Controlled Trial
Buse, John B.
Bergenstal, Richard M.
Glass, Leonard C.
Heilmann, Cory R.
Lewis, Michelle S.
Kwan, Anita Y. M.
Hoogwerf, Byron J.
Rosenstock, Julio
[J]. ANNALS OF INTERNAL MEDICINE, 2011, 154 (02) : 103 - +

← 1 2 3 4 5 6 7 →